Treatments and clinical outcomes of patients infected with COVID-19
| Variable | National Institutes of Health clinical spectrum | P-value | |||
|---|---|---|---|---|---|
| Total (n=214) |
Asymptomatic/mild illness (n=104) |
Moderate illness (n=63) |
Severe/critical illness (n=47) |
||
| Treatment | <0.001 | ||||
| Oxygen therapy | 39 (18.2) | 1 (1.0) | 1 (1.6) | 38 (80.9) | |
| HFNC apply | 7 (3.3) | 0 (0) | 0 (0) | 7 (14.9) | |
| Mechanical ventilation | 1 (0.5) | 0 (0) | 0 (0) | 1 (2.1) | |
| Antiviral agent | |||||
| Lopinavir/ritonavir | 123 (57.5) | 39 (37.5) | 47 (74.6) | 37 (78.7) | <0.001 |
| Hydroxychloroquine | 31 (14.5) | 7 (6.7) | 10 (15.9) | 14 (29.8) | 0.001 |
| Pneumonia on chest X-ray | |||||
| Total | 109 (50.9) | 0 (0) | 62 (98.4) | 47 (100) | <0.001 |
| On admission | 60 (28.0) | 0 (0) | 29 (46.0) | 31 (66.0) | <0.001 |
| New onset during hospital stay | 49 (22.9) | 0 (0) | 33 (52.4) | 16 (34.0) | <0.001 |
| Discharge type | <0.001 | ||||
| Normal discharge |
140 (65.4) | 54 (51.9) | 52 (82.5) | 34 (72.3) | |
| Residential treatment centers |
61 (28.5) | 50 (48.1) | 11 (17.5) | 0 (0) | |
| Transfer to tertiary hospital | 11 (5.1) | 0 (0) | 0 (0) | 11 (23.4) | |
| Expire | 2 (0.9) | 0 (0) | 0 (0) | 2 (4.3) | |
| Length of stay in hospital (d) | 27.4±16.2 | 20.7±10.5 | 32.3±13.7 | 35.6±22.7 | <0.001 |
Values are presented as number (%) or mean±standard deviation.
COVID-19, coronavirus disease 2019; HFNC, high flow nasal cannula.
aA person should not exhibit fever without taking fever reducers and show improvements in clinical symptoms. Thereafter, the person should test negative on real-time RT-PCR tests twice in a row with at least a 24-hour interval. bMild cases who do not need hospitalization were shifted to residential treatment centers. cP-value by ANOVA.
P-value was calculated by chi-square test.